Robert Connelly joined Elicio as CEO in October 2018. Elicio is a novel cancer immunotherapy company based on groundbreaking science from the Koch Institute of Cancer Research at MIT. He is a prolific entrepreneur and company builder/leader with 30+ years of experience in the Life Sciences sector. Since 2000, Connelly has been the CEO and/or Chairman of startup or early stage novel therapeutic companies, including as the founding CEO and first employee of Domantis (sold to GSK in 2007 for $454 million, the largest all-cash purchase of a preclinical company at that date), CEO of Pulmatrix (NASDAQ:PULM) and CEO of Axcella Health (NASDAQ:ALXA).
Connelly also served as a Venture Partner with Flagship Pioneering from 2013 to October 2018, working on the creation and management of 5 portfolio companies, including as a CEO of Axcella, Board member of Kaleido (NASDAQ:KLDO) and Kintai, Chairman of Aero Designs and Founding CEO of WikiCell Designs (Aero and Wiki merged into Incredible Foods in 2013). Connelly has personally raised over $300 million in financing for his companies and participated in over $250 million in financings as a Chairman or Director. He’s led many partnering transactions for his companies, including product and platform license, government and foundation funding and M&A transactions, while launching many innovative platforms and products across disease areas.
Connelly began his career in the diagnostics division of Abbott Laboratories, spending over 11 years in sales, sale-management, marketing and strategic marketing positions of increasing responsibility. He then spent 6 years with Bioveris (acquired by Roche for $1.6 billion) as SVP of Sales and Marketing and General Manager of the Life Sciences Business Unit, taking a lead marketing and investor communication roles in the company’s public financings of over $300 million. Connelly currently also serves as a Director on the Board of Anchiano (NASDAQ:ANCN), a clinical-stage cancer therapeutics company.